HENGRUI PHARMA - Jiangsu Hengrui Pharmaceutical Co., Ltd.’s Progress Announcement on Repurchasing Company Shares A
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceutical Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 1276)
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company") published the following announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). They are listed below for reference only.
By order of the board of directors
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Chairman
Mr. Sun Piaoyang
Shanghai, China
August 4, 2026
As at the date of this announcement, the members of the Board include (i) executive directors Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) non-executive director Ms. Guo Congzhao; and (iii) independent non-executive directors Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.
Securities code: 600276 Securities abbreviation: Hengrui Pharmaceutical Announcement Number: Lin 2026-112
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Announcement on the progress of repurchasing company shares
A
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The first disclosure date of the repurchase plan is 2025/8/21
The implementation period of the buyback plan is August 20, 2025 ~ August 19, 2026
Estimated repurchase amount: 1 million yuan to 2 million yuan
□Reduce registered capital
√Used for employee stock ownership plans or equity incentives
Repurchase purpose
□Used to convert company convertible bonds
□To protect the company’s value and shareholders’ rights and interests
The cumulative number of shares repurchased is 13.7502 million shares
The cumulative number of shares repurchased accounts for 0.21% of the total share capital.
The cumulative repurchased amount is 853.0848 million yuan
Actual repurchase price range: 45.30 yuan/share~70.00/yuan/share
- Basic information on share repurchase
Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 18th meeting of the ninth board of directors on August 20, 2025, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's A Shares through Centralized Bidding Transactions", and agreed that the company would use its own funds to repurchase the company's shares through centralized bidding transactions for the implementation of the A-share employee stock ownership plan. The repurchase price shall not exceed RMB 90.85 per share (inclusive), and the total repurchase funds shall not be less than RMB 1 billion and shall not exceed RMB 2 billion. The repurchase period is within 12 months from the date the board of directors considers and approves the share repurchase plan. For details, please refer to the "Repurchase Report on the Repurchase of the Company's A Shares through Centralized Bidding Transactions" (Announcement No.: Lin 2025-130) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).
- Progress of share repurchase
In accordance with the relevant provisions of the "Share Repurchase Rules of Listed Companies" and "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares", the progress of the company's share repurchase is now announced as follows:
In July 2026, the company repurchased 280,000 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares accounted for 0.004% of the company's total share capital. The highest purchase price was RMB 54.05 per share and the lowest price was RMB 53.75 per share. The total amount paid was RMB 15.0888 million (excluding transaction fees).
As of July 31, 2026, the company's share repurchase plan has repurchased a total of 13.7502 million shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares accounted for 0.21% of the company's total share capital. The highest purchase price was RMB 70.00 per share and the lowest price was RMB 45.30. Yuan/share, the total amount paid was RMB 853.0848 million (excluding transaction fees).
The above-mentioned repurchase complies with the provisions of relevant laws and regulations and the company's established share repurchase plan.
- Other matters
The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions during the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.
August 4, 2026